Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens.
Sara W QuistSophie Te DorsthorstRoel D FreriksMaarten J PostmaCarel B HoyngFreekje van AstenPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2024)
Screening for HCQ retinopathy is cost-effective, but delayed initiation and a reduced frequency, using solely an SD-OCT, are more cost-effective. We recommend screening with an SD-OCT and a biennial regimen after 10 years for low-risk patients, an annual regimen after 5 years for intermediate- and high-risk patients.